{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:54:03Z","timestamp":1791222843760,"version":"4.1.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2015,3,23]],"date-time":"2015-03-23T00:00:00Z","timestamp":1427068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"DOI":"10.1371\/journal.ppat.1004722","type":"journal-article","created":{"date-parts":[[2015,3,23]],"date-time":"2015-03-23T18:36:57Z","timestamp":1427135817000},"page":"e1004722","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":75,"title":["Persistence of Transmitted HIV-1 Drug Resistance Mutations Associated with Fitness Costs and Viral Genetic Backgrounds"],"prefix":"10.1371","volume":"11","author":[{"given":"Wan-Lin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger D.","family":"Kouyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrg","family":"B\u00f6ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Yerly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klimkait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Aubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra U.","family":"Scherrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohaned","family":"Shilaih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Hinkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bonhoeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huldrych F.","family":"G\u00fcnthard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Swiss HIV Cohort Study (SHCS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,3,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"FJ Palella","year":"1998","journal-title":"The new England journal of medicine"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1086\/597352","article-title":"Long\u2010Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment\u2013Experienced Patients in Switzerland","volume":"48","author":"V von Wyl","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1086\/644505","article-title":"Transmission of Drug\u2010Resistant HIV\u20101 Is Stabilizing in Europe","volume":"200","author":"J Vercauteren","year":"2009","journal-title":"J Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1097\/00002030-200111230-00010","article-title":"Acute HIV infection: impact on the spread of HIV and transmission of drug resistance","volume":"15","author":"S Yerly","year":"2001","journal-title":"AIDS"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1097\/QAD.0b013e3282f0b685","article-title":"Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey","volume":"21","author":"S Yerly","year":"2007","journal-title":"AIDS"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Little SJ. Transmission and prevalence of HIV resistance among treatment-naive subjects. Antiviral Therapy 2000;","DOI":"10.1177\/135965350000500111"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1086\/650001","article-title":"Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome","volume":"50","author":"MR Jakobsen","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1086\/432916","article-title":"Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management","volume":"192","author":"AMJ Wensing","year":"2005","journal-title":"J Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1089\/aid.2011.0284","article-title":"Southern Africa Treatment And Resistance Network (SATuRN). Primary drug resistance in South Africa: data from 10 years of surveys","volume":"28","author":"J Manasa","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1097\/QAD.0b013e32834bbbe9","article-title":"Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients","volume":"25","author":"AF Aghokeng","year":"2011","journal-title":"AIDS"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"DE Bennett","year":"2009","journal-title":"PLoS ONE"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/archinte.167.16.1782","article-title":"Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types","volume":"167","author":"V von Wyl","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1128\/JVI.02579-07","article-title":"Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection","volume":"82","author":"SJ Little","year":"2008","journal-title":"Journal of Virology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/infdis\/jit310","article-title":"Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection","volume":"208","author":"KJ Metzner","year":"2013","journal-title":"J Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/infdis\/jiq167","article-title":"Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes","volume":"203","author":"V Jain","year":"2011","journal-title":"J Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Metzner KJ, Leemann C, Di Giallonardo F, Grube C, Scherrer AU, Braun D, et al. Reappearance of Minority K103N HIV-1 Variants after Interruption of ART Initiated during Primary HIV-1 Infection. PLoS ONE 2011;","DOI":"10.1371\/journal.pone.0021734"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/01.aids.0000131391.91468.ff","article-title":"Persistence of primary drug resistance among recently HIV-1 infected adults","volume":"18","author":"JD Barbour","year":"2004","journal-title":"AIDS"},{"key":"ref18","first-page":"104","article-title":"HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo","volume":"134","author":"J Martinez-Picado","year":"2008"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","article-title":"Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study","volume":"11","author":"L Wittkop","year":"2011","journal-title":"The Lancet Infectious Diseases"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1001\/jama.288.2.181","article-title":"Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons","volume":"288","author":"RM Grant","year":"2002","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1128\/JVI.02712-06","article-title":"The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions","volume":"81","author":"M-E Cong","year":"2007","journal-title":"Journal of Virology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJMoa013552","article-title":"Antiretroviral-drug resistance among patients recently infected with HIV","volume":"347","author":"SJ Little","year":"2002","journal-title":"The New England Journal of mMedicine"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/589297","article-title":"Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel","volume":"47","author":"MS Hirsch","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ije\/dyp321","article-title":"Cohort profile: the Swiss HIV Cohort study","volume":"39","year":"2010","journal-title":"Int J Epidemiol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0140-6736(99)01122-8","article-title":"Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study","volume":"353","author":"B Ledergerber","year":"1999","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/aid.1998.14.869","article-title":"Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples","volume":"14","author":"HF Gunthard","year":"1998","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/ng.795","article-title":"A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase","volume":"43","author":"T Hinkley","year":"2011","journal-title":"Nature Genetics"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e1002321","DOI":"10.1371\/journal.ppat.1002321","article-title":"Assessing predicted HIV-1 replicative capacity in a clinical setting","volume":"7","author":"RD Kouyos","year":"2011","journal-title":"PLoS Pathog"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/infdis\/jit345","article-title":"Persistence of HIV-1 transmitted drug resistance mutations","volume":"208","author":"H Castro","year":"2013","journal-title":"J Infect Dis"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1128\/JVI.72.5.3520-3523.1998","article-title":"Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants","volume":"72","author":"S Yerly","year":"1998","journal-title":"Journal of Virology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"13907","DOI":"10.1073\/pnas.241300698","article-title":"Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons","volume":"98","author":"JG Garcia-Lerma","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"ref32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1473-3099(10)70264-4","article-title":"Population biological principles of drug-resistance evolution in infectious diseases","volume":"11","author":"PA Wiesch zur","year":"2011","journal-title":"The Lancet Infectious Diseases"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrmicro2319","article-title":"Antibiotic resistance and its cost: is it possible to reverse resistance?","volume":"8","author":"DI Andersson","year":"2010","journal-title":"Nat. Rev. Microbiol."}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.ppat.1004722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T18:54:26Z","timestamp":1651604066000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1004722"}},"subtitle":[],"editor":[{"given":"Ronald","family":"Swanstrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,23]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1004722","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,23]]}}}